{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:55:14Z","timestamp":1782442514580,"version":"3.54.5"},"reference-count":54,"publisher":"Wiley","issue":"2-3","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Psychiatry"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Decisions about using psychotropics during pregnancy are complex as risks of untreated illness are balanced against risks of fetal exposure to medication. The objective was to describe perinatal psychotropic dispensing patterns in New Zealand.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Nationwide data from the New Zealand National Maternity Collection between January 1, 2011 and December 31, 2017 identified 399\u2009715 pregnancies. These were linked with dispensing records to determine the proportion of pregnancies during which at least 1 psychotropic was dispensed. Proportions were calculated separately for each class, year, pregnancy period, and across maternal characteristics. The pattern of dispensing (including discontinuations) was also determined for the 25\u2009841 women who were dispensed at least 1 psychotropic drug prior to pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From the 399\u2009715 pregnancies in the study cohort, 6.6% were dispensed at least 1 psychotropic during pregnancy. Antidepressants (5.1%) were the most dispensed, followed by hypnotics (1.2%), anxiolytics (0.7%), and antipsychotics (0.7%). From the 25\u2009841 pregnancies during which a psychotropic was dispensed pre\u2010pregnancy, 91% and 90% discontinued hypnotics and anxiolytics respectively, prior to or during pregnancy. This was followed by lithium (71%), antipsychotics (66%), and antidepressants (66%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Dispensing of psychotropics during pregnancy occurs in approximately 6.6% of pregnancies in New Zealand. Two\u2010thirds of women (66%) on antidepressants or antipsychotics discontinue dispensing before or during pregnancy. This may have implications for maternal mental health, suggesting there is a need to investigate how healthcare providers and women are making decisions about psychotropic use during pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/appy.12539","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T01:56:21Z","timestamp":1686880581000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perinatal psychotropic dispensing: A descriptive population\u2010based study in <scp>N<\/scp>ew <scp>Z<\/scp>ealand"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6676-4711","authenticated-orcid":false,"given":"Lucy Charlotte","family":"Broughton","sequence":"first","affiliation":[{"name":"School of Pharmacy University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9778-1947","authenticated-orcid":false,"given":"Natalie","family":"Hughes\u2010Medlicott","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Preventive and Social Medicine University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-3306","authenticated-orcid":false,"given":"Alesha","family":"Smith","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r13134"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13608"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13194"},{"key":"e_1_2_9_5_1","unstructured":"Best Practice Advocacy Centre NZ. (2021).Benzodiazepines and zopiclone: Is overuse still an issue?https:\/\/bpac.org.nz\/2021\/benzo-zopiclone.aspx"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867415578344"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/aog.0000000000002046"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13732"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.13352"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-014-0445-4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jmwh.13366"},{"issue":"1","key":"e_1_2_9_12_1","first-page":"44","article-title":"Abrupt discontinuation of psychotropic drugs during pregnancy: Fear of teratogenic risk and impact of counselling","volume":"26","author":"Einarson A.","year":"2001","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02707-z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.12740\/pp\/105906"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-14-242"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-019-0346-5"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12369"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-018-0906-2"},{"issue":"1474","key":"e_1_2_9_19_1","first-page":"45","article-title":"Off label or on trend: A review of the use of quetiapine in New Zealand","volume":"131","author":"Huthwaite M.","year":"2018","journal-title":"New Zealand Medical Journal"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-021-01423-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2020.09.008"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)00003-1"},{"issue":"1454","key":"e_1_2_9_23_1","first-page":"10","article-title":"Ethnic inequality in diagnosis with depression and anxiety disorders","volume":"130","author":"Lee C. H.","year":"2017","journal-title":"New Zealand Medical Journal"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717711168"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171600283X"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-013-1419-2"},{"key":"e_1_2_9_27_1","unstructured":"Ministry of Health. (2018\u20132019).Mental health and addiction: service use 2018\/19 tables."},{"key":"e_1_2_9_28_1","unstructured":"Ministry of Health. (2019 December 9).New Zealand obstetric ultrasound guidelines.https:\/\/www.health.govt.nz\/publication\/new-zealand-obstetric-ultrasound-guidelines"},{"key":"e_1_2_9_29_1","unstructured":"Ministry of Health. (2021a).National Maternity Collection.https:\/\/www.health.govt.nz\/nz-health-statistics\/national-collections-and-surveys\/collections\/national-maternity-collection"},{"key":"e_1_2_9_30_1","unstructured":"Ministry of Health. (2021b).Pharmaceutical Collection.https:\/\/www.health.govt.nz\/nz-health-statistics\/national-collections-and-surveys\/collections\/pharmaceutical-collection"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-018-0844-z"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.12.014"},{"key":"e_1_2_9_33_1","unstructured":"New Zealand Government. (2018).He Ara Oranga Report of the Government Inquiry into Mental Health and Addiction.https:\/\/mentalhealth.inquiry.govt.nz\/about-the-inquiry\/"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3838"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201600408"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612222"},{"key":"e_1_2_9_37_1","unstructured":"Perinatal and Maternal Mortality Review Committee. (2019).Te P\u016brongo \u0101\u2010Tau Tekau m\u0101 Toru o te Komiti Arotake Mate P\u0113pi Mate Whaea Hokihe | Thirteenth Annual Report of the Perinatal and Maternal Mortality Review Committee. Wellington."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007390"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.07.034"},{"key":"e_1_2_9_40_1","unstructured":"Pharmac. (2022 July 1).Rules of the Schedule Ng\u0101 Ture o te R\u0101rangi Rongo\u0101.https:\/\/pharmac.govt.nz\/pharmaceutical-schedule\/general-rules-section-a\/"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1744-4"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.03.005"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16210"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.02.018"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2016.1205026"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674211025699"},{"key":"e_1_2_9_47_1","volume-title":"Prescribing guidelines in psychiatry","author":"Taylor D.","year":"2018"},{"key":"e_1_2_9_48_1","unstructured":"Te hiringa hauora (Health Promotion Agency). (2020).Mental Health in Aotearoa.https:\/\/www.hpa.org.nz\/sites\/default\/files\/Mental_Health_Aotearoa_Insight_2020.pdf"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15r10483"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04943"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.06.009"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-020-03293-0"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3182306847"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23604"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144474"}],"container-title":["Asia-Pacific Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/appy.12539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T01:40:57Z","timestamp":1692754857000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/appy.12539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":54,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/appy.12539"],"URL":"https:\/\/doi.org\/10.1111\/appy.12539","archive":["Portico"],"relation":{},"ISSN":["1758-5864","1758-5872"],"issn-type":[{"value":"1758-5864","type":"print"},{"value":"1758-5872","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12539"}}